Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

医学 曲妥珠单抗 曲妥珠单抗 转移性乳腺癌 内科学 肿瘤科 多西紫杉醇 危险系数 乳腺癌 不利影响 癌症 胃肠病学 置信区间
作者
Sara A. Hurvitz,Luc Dirix,Judit Kocsis,Giulia Bianchi,Janice Lu,J. Vinholes,Ellie Guardino,Chunyan Song,Barbara Tong,Vivian Ng,Yu-Waye Chu,Edith A. Perez
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:31 (9): 1157-1163 被引量:393
标识
DOI:10.1200/jco.2012.44.9694
摘要

PURPOSE: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable thioether linker, has shown clinical activity in single-arm studies enrolling patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC) whose disease had progressed on HER2-targeted therapy in the metastatic setting. PATIENTS AND METHODS: Patients (N = 137) with HER2-positive MBC or recurrent locally advanced breast cancer were randomly assigned to trastuzumab plus docetaxel (HT; n = 70) or T-DM1 (n = 67) as first-line treatment until disease progression or unacceptable toxicity. Primary end points were investigator-assessed progression-free survival (PFS) and safety. Key secondary end points included overall survival (OS), objective response rate (ORR), duration of objective response, clinical benefit rate, and quality of life. RESULTS: Median PFS was 9.2 months with HT and 14.2 months with T-DM1 (hazard ratio, 0.59; 95% CI, 0.36 to 0.97); median follow-up was approximately 14 months in both arms. ORR was 58.0% (95% CI, 45.5% to 69.2%) with HT and 64.2% (95% CI, 51.8% to 74.8%) with T-DM1. T-DM1 had a favorable safety profile versus HT, with fewer grade ≥ 3 adverse events (AEs; 46.4% v 90.9%), AEs leading to treatment discontinuations (7.2% v 34.8%), [corrected] and serious AEs (20.3% v 25.8%). Preliminary OS results were similar between treatment arms; median follow-up was approximately 23 months in both arms. CONCLUSION: In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a favorable safety profile, versus HT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
1秒前
kailanshi发布了新的文献求助10
1秒前
lilili的应助被科研通管家采纳,获得10
1秒前
2秒前
英姑的应助被科研通管家采纳,获得10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
jin的应助被科研通管家采纳,获得20
2秒前
2秒前
天天快乐的应助被科研通管家采纳,获得10
2秒前
2秒前
李健的应助被科研通管家采纳,获得10
2秒前
ccq的应助被科研通管家采纳,获得10
2秒前
wanci的应助被科研通管家采纳,获得10
2秒前
lilili的应助被科研通管家采纳,获得10
3秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
3秒前
3秒前
丘比特的应助被科研通管家采纳,获得10
3秒前
3秒前
xing_xing的应助被科研通管家采纳,获得20
3秒前
大个的应助被科研通管家采纳,获得10
3秒前
上官若男的应助被风中的竺采纳,获得10
3秒前
斯文败类的应助被科研通管家采纳,获得10
3秒前
英姑的应助被科研通管家采纳,获得10
3秒前
华仔的应助被科研通管家采纳,获得10
3秒前
skychen发布了新的文献求助10
4秒前
4秒前
沉吟发布了新的文献求助10
4秒前
lilili的应助被科研通管家采纳,获得10
4秒前
kk发布了新的文献求助10
4秒前
xing_xing的应助被科研通管家采纳,获得20
4秒前
Subwaid的应助被执着的飞荷采纳,获得10
4秒前
大模型的应助被科研通管家采纳,获得10
4秒前
Lucas的应助被科研通管家采纳,获得10
4秒前
JeanetteJin发布了新的文献求助10
4秒前
4秒前
花小羊发布了新的文献求助10
5秒前
WXD发布了新的文献求助10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177654
求助须知:如何正确求助?哪些是违规求助? 9568503
关于积分的说明 21799551
捐赠科研通 7772253
什么是DOI,文献DOI怎么找? 3432428
关于科研通互助平台的介绍 2556594
邀请新用户注册赠送积分活动 2478011